Project Grant R01CA304166
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $485K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Farmington, CT 06030, USA
Similar Awards
- Federal Grant Award Summary The University of Connecticut Health Center received a $499,568 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2026 through May 31, 2031. This award funds the development and validation of a novel "cap-linker" strategy to enhance the therapeutic efficacy and safety profile of oncolytic viral therapies, specifically engineered vesicular stomatitis virus (VSV) variants...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Project Grant Award Summary Yale University received a $482,312 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop a novel immunotherapy approach targeting regulatory T (Treg) cells in cancer patients. The research, performed in West Haven, Connecticut, runs from April 2, 2026 through March 31, 2031 and focuses on inactivating Treg cells through targeted FOXP3 protein degradation. This approach aims to overcome...
- Federal Grant Award Summary The National Cancer Institute awarded Yale University a $478,532 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This research initiative will investigate the biological and clinical significance of spatial immune heterogeneity in non-small cell lung cancer (NSCLC), with particular focus on characterizing how the spatial distribution of tumor-infiltrating lymphocytes (TILs) and tertiary...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai a $697,131 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period May 1, 2026 through April 30, 2031. This award supports fundamental research designed to elucidate the myeloid-stromal crosstalk mechanisms that drive immune suppression and tumor progression in colorectal cancer (CRC), particularly in microsatellite-stable cases resistant to immune checkpoint...
- Federal Project Grant Award Summary The University of Utah received a $518,090 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) beginning June 1, 2026 and extending through May 31, 2031. This five-year award supports fundamental research investigating the regulation of anti-tumor immunity by CX3CL1 (C-X3-C Motif Chemokine Ligand 1), a tumor-produced molecule that inhibits T cell-mediated cancer immunotherapy responses. The research...
- Federal Grant Award Summary The National Cancer Institute awarded the University of California, Irvine a $648,626 Project Grant on April 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI). The research addresses a critical gap in understanding why PD-1 inhibitor monotherapy and dual checkpoint inhibitor combinations fail in the majority of cancer patients. The study will examine...
- Federal Project Grant Award Summary Yale University received a $130,490 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded June 1, 2026, with a completion date of May 31, 2028. This award supports biomedical training and research career development initiatives focused on understanding the cellular and molecular mechanisms of early-onset colorectal cancer (EOCRC). The project addresses a significant public health concern—while...
- Federal Grant Award Summary The National Cancer Institute awarded $770,666 through its Cancer Biology Research program (CFDA 93.396) to the University of Colorado, Boulder on March 19, 2026, with completion targeted for February 28, 2028. This project grant supports fundamental research investigating splicing-mediated dysregulation of interferon signaling in cancer, with specific focus on how transposon-derived exonized variants of the IFNAR2 gene contribute to cancer treatment resistance. The...